The efficacy of GIP/GLP1 receptor co-agonists on glucose control is surprising, and allows to reach glucose levels similar to diabetes remission in a greater percentage of patients compared to other treatments
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
One potential reason leptin has not panned out as a therapy on its own is a phenomenon known as leptin resistance. Thats when the body becomes desensitized to the hormone at higher levels, causing a person to feel hungry and eat more even though they have sufficient body fat
Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy
The hypothalamus with its key regions, including ARC, LHA and closely related PVN, serving as the feeding or hunger center, VMN acting as the satiety center and NTS conveying the peripheral signals, particularly from the gut to the feeding centers, are implicated in appetitive behavior
Semaglutide was associated with a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety and a 47% lower risk of worsening substance use disorder
